Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. reported a modest increase in total revenue and profit for the first half of 2025, driven by drug sales, R&D services, and license income. The company’s international strategy has led to significant growth in overseas product sales, particularly in the United States, enhancing its global profitability. The company has successfully expanded its product approvals across multiple countries, with notable achievements in the marketing of its anti-PD-1 monoclonal antibody, HANSIZHUANG, and the biosimilar HANQUYOU. Strategic licensing agreements further bolster its international commercial footprint.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of biologic drugs. The company is known for its innovative research and development in monoclonal antibodies, with a significant market presence in China and expanding international reach.
Average Trading Volume: 1,357,681
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.38B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.